首页 › 基金 › REGENERON PHARMACEUTICALS, INC. › PBLS
REGENERON PHARMACEUTICALS, INC. 对 PBLS 的持仓历史
Parabilis Medicines, Inc. · 医疗保健
REGENERON PHARMACEUTICALS, INC. 在 Q3 2026 的 13F 申报中披露持有 PBLS(Parabilis Medicines, Inc.)4,166,666 股,市值约 US$134.5M,约占其申报组合的 74.90%,在其申报持仓中市值排名第 1 位。 REGENERON PHARMACEUTICALS, INC. 最近 2 个申报季度中有 2 个季度披露了 PBLS 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-06 · 来源: SEC EDGAR Form 13F-HR
REGENERON PHARMACEUTICALS, INC. 对 PBLS 的持仓演变
REGENERON PHARMACEUTICALS, INC. 于 Q2 2026 首次披露 PBLS 持仓:4,166,666 股(约 US$114.0M)。 该持仓在 Q3 2026 达到峰值 4,166,666 股,市值约 US$134.5M。 在 2 次申报中,REGENERON PHARMACEUTICALS, INC. 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 4,166,666 股、市值约 US$134.5M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 4.17M | $114.04M | 新进 |
| Q3 2026 | 4.17M | $134.54M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PBLS 与 13F 数据
PBLS(Parabilis Medicines, Inc.)属于医疗保健行业。我们追踪的基金中还有 90 只申报持有 PBLS,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$791.9M), ARCH Venture Management, LLC (US$175.5M), venBio Partners LLC (US$144.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PBLS 的基金
- RA CAPITAL MANAGEMENT, L.P. 28.93M 股 · $791.91M · Q2 2026
- ARCH Venture Management, LLC 6.41M 股 · $175.52M · Q2 2026
- venBio Partners LLC 5.27M 股 · $144.15M · Q2 2026
- Alphabet Inc. 4.92M 股 · $134.65M · Q2 2026
- Nextech Invest Ltd. 4.66M 股 · $127.63M · Q2 2026
- Cormorant Asset Management, LP 4.62M 股 · $126.33M · Q2 2026
- Siren, L.L.C. 2.99M 股 · $81.90M · Q2 2026
- 法拉龙资本管理 2.37M 股 · $64.82M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.37M 股 · $64.82M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.92M 股 · $52.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.88M 股 · $51.47M · Q2 2026
- General Catalyst Group Management, LLC 1.60M 股 · $43.82M · Q2 2026
更多关于 REGENERON PHARMACEUTICALS, INC.
常见问题
How long has REGENERON PHARMACEUTICALS, INC. held PBLS?
REGENERON PHARMACEUTICALS, INC. has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is REGENERON PHARMACEUTICALS, INC.'s current position in PBLS?
As of Q3 2026, REGENERON PHARMACEUTICALS, INC. holds 4.17M shares of PBLS (Parabilis Medicines, Inc.), valued at $134.54M, representing 74.90% of its reported portfolio and ranking #1.
Has REGENERON PHARMACEUTICALS, INC. been buying or selling PBLS?
In the latest 13F filing (Q3 2026), REGENERON PHARMACEUTICALS, INC. held unchanged its position in PBLS. The position peaked in Q3 2026 at 4.17M shares.
Which other funds hold PBLS?
Other major institutional holders of PBLS include RA CAPITAL MANAGEMENT, L.P., ARCH Venture Management, LLC, venBio Partners LLC, among 90 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.